Company news
Celldex Therapeutics, Inc. (NASDAQ:CLDX) news
Celldex Therapeutics, Inc. news releases on 6ix. Latest, Sep 22, 2026: Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies…
Press releases & updates
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
September 22, 2026
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
August 6, 2026
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
July 21, 2026
Celldex Announces Planned Transition of Chief Financial Officer
July 15, 2026
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
June 14, 2026
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
June 14, 2026
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
June 10, 2026
Celldex Reports First Quarter Financial Results and Provides Corporate Update
May 7, 2026
Celldex to Present at Upcoming Investor Conference
April 13, 2026
Celldex Announces Proposed Public Offering of Common Stock
April 1, 2026
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
March 31, 2026
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
March 26, 2026
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
March 1, 2026
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Dis...
February 28, 2026
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
February 27, 2026
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at ...
February 26, 2026
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
February 25, 2026
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
February 25, 2026
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
February 23, 2026
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
December 8, 2025
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 9, 2025
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
November 9, 2025
Celldex to Present at Upcoming Investor Conferences
November 6, 2025
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20
November 6, 2025
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patient...
November 5, 2025
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
November 5, 2025
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
October 29, 2025
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
September 16, 2025
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
September 8, 2025
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
August 18, 2025
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 6, 2025
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
June 13, 2025
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
June 11, 2025
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
June 9, 2025
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
June 5, 2025
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 7, 2025
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
May 4, 2025
Celldex Therapeutics to Present at Upcoming Investor Conferences
March 3, 2025
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
March 2, 2025
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
February 28, 2025
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
February 26, 2025
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
December 18, 2024
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
November 19, 2024
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 5, 2024
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
October 25, 2024
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
October 24, 2024
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 24, 2024
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
September 15, 2024
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 7, 2024
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
July 28, 2024